Diagnosis of pancreatic allograft rejection by measurement of urinary radioimmunoreactive insulin.
The accurate, early, and sensitive diagnosis of pancreatic allograft rejection is one of the major problems in clinical pancreas transplantation today. Pancreaticocystotomy is a popular technique for pancreas transplantation that permits simple and frequent urinary chemistry examinations. In this experiment, 20 mongrel dogs with a bladder-drained pancreatic transplant had serial monitoring of urinary amylase (UA) and urinary insulin (UI). The mean UI in the nonrejection state was 9.6 +/- 12 mIU/L. In eight dogs varying degrees of rejection were documented by histopathology. All three animals having severe acute rejection had high levels of IU (all greater than 300-800 mIU/L). Of the five animals with mild-to-moderate rejection, all had significant UI elevations to greater than 100 mIU/L but none had elevations above 200 mIU/L (P less than 0.05 for all groups). Ten animals were treated with prednisone, Imuran, and cyclosporine (CsA), and five of these dogs had good graft function for greater than 14 days, during which the mean UI was extremely low (11 +/- 6.4 mIU/L, P less than 0.05). These values were not significantly different from the 0-14-day values for three pancreas autotransplants with bladder drainage (8.9 +/- 7.2 mIU/L, P less than 0.05). All rejections were preceded by significant rises of UI occurring two to five days prior to rejection. In seven animals, early graft dysfunction (1-4 days) developed, with total graft necrosis by five days. This graft injury was presumably caused by preservation damage or early vascular thrombosis and was associated with early (1-4 days) marked elevations of the UI (greater than 300 mIU/L). None of the animals with grafts surviving to rejection at seven days or more had these early severe elevations, and thus these early UI rises are pathognomonic of graft damage. In contrast, UA and lipase showed inconsistent association with rejection or early damage, although falls in UA generally occurred at or following the time of rejection. Marked daily variations in UA measurements were the most difficult aspect of UA monitoring. Serial electromagnetic flow probe studies of blood flow to the pancreas graft showed a good correlation between loss of blood flow and rises in UI associated with early graft injury. These results suggested that the UI assay gives a sensitive, early, accurate, and specific differential prediction of pancreas graft dysfunction. Specifically, the UI assay appears to be of value not only in the early differential diagnosis of graft injury and graft rejection, but also in the assessment of the severity of rejection.(ABSTRACT TRUNCATED AT 400 WORDS)
D000681:Amylases / Q000652:urine; D000818:Animals; D004285:Dogs; D055590:Electromagnetic Phenomena; D006084:Graft Rejection / Q000187:drug effects; D006085:Graft Survival; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism / Q000652:urine*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000098:blood supply / Q000378:metabolism; D016381:Islets of Langerhans Transplantation; D011184:Postoperative Period; D011863:Radioimmunoassay / Q000379:methods; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D007328:Insulin; D000681:Amylases